

## **JDS Therapeutics, LLC and its subsidiary Nutrition 21, LLC complete \$16 Million Series B Round of Institutional Equity Financing**

**Purchase, NY** - (October 22, 2015) – JDS Therapeutics, LLC (“JDS”), a privately held specialty pharmaceutical company and its Nutrition 21 LLC nutritional ingredient subsidiary, announced today that it has closed a \$16 million Series B institutional equity financing round led by 1315 Capital, a Philadelphia-based investment firm specializing in healthcare.

"We are delighted to welcome 1315 Capital to our investor group. This \$16 million financing will allow us to support and accelerate our high growth specialty pharmaceutical and nutritional ingredient business platforms. In addition, we expect to continue our strong investment commitment to the protection and expansion of our substantial intellectual property portfolio," states Michael Satow, the President and CEO of JDS.

According to Michael Koby, a Partner at 1315 Capital, "1315 Capital is excited to be partnering with the JDS team. We are highly enthusiastic about the growth prospects and opportunities within the company's multiple business platforms."

### **About JDS Therapeutics, LLC and Nutrition 21 LLC**

JDS Therapeutics, LLC is a specialty pharmaceutical company that develops, manufactures and markets products for women's health. JDS's wholly-owned subsidiary, Nutrition 21, is a leader in the nutritional supplement industry. Nutrition 21 is a developer and marketer of efficacious, high-value, clinically substantiated ingredients for dietary supplements, medical foods and beverages, including Chromax® chromium picolinate and Nitrosigine® bonded arginine silicate. JDS and Nutrition 21 currently hold over 100 issued and pending patents on natural, bioactive compounds that support human health and sports nutrition.

For more information visit [www.JDStherapeutics.com](http://www.JDStherapeutics.com) and [www.Nutrition21.com](http://www.Nutrition21.com)

### **About 1315 Capital**

1315 Capital provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies. These investment areas are attractive largely due to numerous niche market segments and business models which can be scaled in a capital efficient manner. 1315 Capital invests with high-quality management teams with the proven ability to rapidly grow small platform companies into large and important businesses.

For more information visit [www.1315capital.com](http://www.1315capital.com)

XXX